BMP7 and Stroke: However, in vivo administration is limited by the short half-life and the large amounts of biologically active BMP7 that need to be administered (at least 10 mg/kg body weight) [8], which might explain why recombinant BMP7 reduced the infarct volume in some, but not all experimental stroke studies [4,7-9].